Novanta earnings date
Novanta (NOVTN) Q3 2026 Earnings Report
MX:NOVTN Q3 2026 EPS Results
- Actual EPS
- MXN 19.37
- Consensus EPS
- MXN 17.84
- Beat/Miss
- Beat by +MXN 1.53
- One Year Ago EPS
- MXN 16.05
MX:NOVTN Q3 2026 Revenue Results
- Actual Revenue
- MXN 5.63B
- Expected Revenue
- MXN 5.55B
- Beat/Miss
- Beat by +MXN 73.57M
- YoY Revenue Growth
- +23.07%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/09/2026
- Time
- After Close
- Conference Call
- Monday, November 9, 2026
Novanta's next earnings date is estimated for March 2, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive overall. Novanta reported broad-based revenue, organic growth, bookings, backlog, adjusted EBITDA, adjusted EPS, and cash-flow gains; completed and integrated its largest acquisition; and highlighted substantial product, design-win, and end-market momentum. The principal challenges were temporary Stockport production and shipment issues, lower near-term gross margins, a decline in precision medicine revenue, manufacturing-transition costs, tight component supply, and higher leverage after the acquisition. Management characterized the major operational issues as temporary and maintained strong 2026 and 2027 growth expectations.
For the fourth quarter of 2026, Novanta expects GAAP revenue to be approximately $306 million-$312 million, reported growth of 18% to 21%, organic revenue growth of 5% to 7%, and approximately $35 million of revenue from Riverpoint Medical; adjusted EBITDA is expected to be between $76 million and $79 million, representing growth of 25%-30% year over year and approximately 25% EBITDA margin, approximately 150 basis points higher than the prior year, while adjusted diluted earnings per share is expected to be in the range of $0.91-$0.96. For full-year 2026, it expects GAAP revenue of approximately $1,135 million -$1,140 million, reported growth of approximately 16%, organic growth of approximately 7%, adjusted gross margins of approximately 46.5%, non-GAAP operating expenses of approximately 27% of sales, depreciation expense of approximately $19 million, stock compensation expense of approximately $38 million, interest expense of approximately $23 million, a non-GAAP tax rate of approximately 21%, diluted weighted average shares outstanding of approximately 42 million, adjusted EBITDA between $274 million and $277 million, year-over-year growth of 24%-25%, adjusted diluted earnings per share in the range of $3.66 to $3.71, year-over-year growth of 11%-13%, operating cash flow of approximately $200 million, year-end gross debt of approximately $818 million, gross leverage ratio of 2.6x, and net leverage of approximately 2.1. Medical Solutions is expected to deliver 2% to 4% organic growth, Automation Enabling Technologies had an outlook of 12% to14% growth, precision medicine is expected to return to growth in late 2027, production in Stockport is expected to resume in the first quarter, and Novanta currently expects a 2027 outlook of more than 15% reported growth and more than 20% adjusted EBITDA growth, with gross margins expected to expand at least 100 basis points next year and a long-term algorithm of mid to high single-digit organic growth.
- Strong Third-Quarter Revenue and Organic GrowthRevenue grew 23% on a reported basis to $305 million, including organic growth of nearly 10%, which Novanta described as its strongest organic growth in more than three years.
- Record Adjusted EBITDA and Margin ExpansionAdjusted EBITDA increased 38% year over year to $80 million, representing a 26% adjusted EBITDA margin, the highest in Novanta's history and an expansion of 290 basis points year over year.
- Adjusted EPS Growth Ahead of ExpectationsAdjusted EPS increased 21% year over year to $1.05 and came in above management's expectations.
- Bookings and Backlog MomentumCustomer bookings grew 29% in the quarter, or 18% excluding Riverpoint Medical, producing a 1.08 book-to-bill ratio. Backlog reached $543 million, with core backlog up 14% year over year.
- Record Operating Cash FlowThird-quarter operating cash flow was $39 million compared with $8 million in the prior-year quarter. Year-to-date operating cash flow was $156 million versus $55 million last year, and the company expects approximately $200 million for full-year 2026, a company record and more than 3x 2025's level.
- Riverpoint Medical Acquisition Closed and Integrating WellNovanta closed the largest acquisition in its history, Riverpoint Medical, in July. Riverpoint contributed approximately $33 million of third-quarter revenue, performed in line with expectations, had margins in line with the acquisition outlook, and was integrating well.
- Greater Medical and Recurring Revenue ExposureMedical end markets represented 53% of revenue in the quarter and were approaching 60% on a full-year basis including Riverpoint. Recurring consumables across sports medicine, minimally invasive surgery, and surgical robotics represented roughly 25% of revenue.
- Innovation and New Product MomentumNew product revenue grew 23% in the quarter and 47% year to date, lifting the vitality index to approximately 27% of year-to-date sales. Embedded-software-enabled intelligent subsystems represented roughly 25% of revenue and about 75% of new product launches.
- Design-Win GrowthIncremental design wins increased 63% in the quarter and 19% year to date, driven by Novanta's Commercial Excellence playbook.
- Medical Solutions Growth and Surgical PipelineMedical Solutions revenue grew 30% on a reported basis and approximately 3% organically, in line with the company's 2% to 4% outlook. Advanced surgical technologies grew 66% on a reported basis and 12% organically, ahead of the approximately 10% expected, driven by new insufflator launches and medical consumables.
- Riverpoint Consumables and Cross-Selling OpportunityRiverpoint's newest knotless sutures were launched with three leading sports medicine OEMs, more than one-third of Riverpoint's revenue came from recently launched products, and Novanta said it currently addresses only about 10% of the minimally invasive surgical consumables market.
- Automation Enabling Technologies Outperformed OutlookAutomation Enabling Technologies revenue grew 16% year over year, ahead of the 12% to 14% outlook. The segment had a 1.11 book-to-bill ratio, 28% growth in new product revenue, 33% growth in incremental customer design wins, and a 20% vitality index.
- Robotics and Precision Manufacturing GrowthPrecision manufacturing revenue grew 14% year over year, while robotics and automation revenue increased 17%. Robotics and automation had a 1.14 book-to-bill ratio, and the air bearing spindles business was sold out for the next two years.
- New Industrial and Robotics WinsNovanta won a significant share of a leading additive manufacturer's next-generation platform, won a second additive OEM during the quarter, launched a new family of servo drives, introduced the Volcano integrated servo drive and encoder module, won new content on a major orthopedic robotics platform, and formed a strategic partnership to supply servo drives across one leading humanoid developer's robot portfolio.
- Manufacturing Footprint and Systems ProgressNovanta consolidated two factories in the second quarter and launched the closure effort for two more in the third quarter, putting it on track for 18 factories by the end of the first quarter of 2027 versus 21 a year earlier. The company also implemented its new SAP MRP system at two lighthouse centers without disruption.
- Supply Chain MitigationDespite tight and in some cases worsening supplies of rare earth materials and electronic components, Novanta said its teams shielded customers from the impact by building safety stock earlier in the year.
- Raised Full-Year Revenue Outlook and Strong 2027 ExpectationsFull-year 2026 GAAP revenue guidance is approximately $1.135 billion to $1.140 billion, with the low end raised from the prior range, representing approximately 16% reported growth and approximately 7% organic growth. Management currently expects more than 15% reported growth and more than 20% adjusted EBITDA growth in 2027.
- Full-Year Earnings and Cash Flow GuidanceFull-year 2026 adjusted EBITDA guidance is $274 million to $277 million, representing 24% to 25% year-over-year growth, while adjusted diluted EPS guidance is $3.66 to $3.71, representing 11% to 13% growth.
- Fourth-Quarter Growth GuidanceFor the fourth quarter, Novanta expects revenue of approximately $306 million to $312 million, reported growth of 18% to 21%, organic growth of 5% to 7%, adjusted EBITDA of $76 million to $79 million, adjusted EBITDA growth of 25% to 30%, and an adjusted EBITDA margin of approximately 25%.
MX:NOVTN Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 02, 2027 | 2026 (Q4) | 17.10- | 16.79 | ― | ― |
| Nov 09, 2026 | 2026 (Q3) | 17.8419.37 | 16.05 | 20.69% (+3.32) | |
| Aug 05, 2026 | 2026 (Q2) | 15.3116.42 | 14.02 | 17.11% (+2.40) | |
| May 11, 2026 | 2026 (Q1) | 14.3314.94 | 13.65 | 9.46% (+1.29) | |
| Feb 23, 2026 | 2025 (Q4) | 16.2316.79 | 14.02 | 19.74% (+2.77) | |
| Nov 03, 2025 | 2025 (Q3) | 15.0716.05 | 15.68 | 2.35% (+0.37) | |
| Aug 05, 2025 | 2025 (Q2) | 13.5214.02 | 13.47 | 4.11% (+0.55) | |
| May 06, 2025 | 2025 (Q1) | 12.4113.65 | 13.65 | 0.00% (+0.00) | |
| Feb 25, 2025 | 2024 (Q4) | 13.1514.02 | 11.62 | 20.63% (+2.40) | |
| Nov 05, 2024 | 2024 (Q3) | 15.7415.68 | 15.68 | 0.00% (+0.00) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


